Osteoporosis drug may strengthen bones from the inside out

NCT ID NCT01155232

Ongoing Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether taking teriparatide (Forteo) for 24 months can improve bone structure in 100 men and women with osteoporosis. Researchers will use a special CT scan to see changes in bone thickness and microarchitecture at the wrist and shin. The goal is to understand how this drug reduces fracture risk beyond just increasing bone density.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Teriparatide (Forteo) injection
What this could lead to: If successful, this could show that teriparatide strengthens bones by improving their internal structure, not just density, leading to better fracture prevention.
What could go wrong: This is a small, non-randomized study with 100 participants, so results may not apply to everyone. Bone structure changes may not translate to fewer fractures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOPOROSIS

Contacts and locations

Locations

University Health Network, TGH

Toronto, Ontario, M5G 2C4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.